This study looked at the safety and effectiveness of tirzepatide (LY-3298176) in patients with type 2 diabetes (T2D) inadequately controlled by diet and exercise alone. It found that compared to placebo, tirzepatide improved diabetes control and weight in these patients.

The study aimed to evaluate the effectiveness and safety of combining standard-dose pembrolizumab (PEM; Keytruda) with two different doses of ipilimumab (IPI; Yervoy) in patients with advanced melanoma. The study concluded that 200 mg PEM plus 50 mg of IPI showed good effectiveness and reduced toxicity compared to 100 mg IPI.

This study evaluated the effectiveness and safety of idelalisib (Zydelig) combined with rituximab (Rituxan) in the treatment of patients with chronic lymphocytic leukemia (CLL) in a real-world setting. The data supported the effectiveness of this regimen in routine practice for these patients.

This study evaluated the safety of eliminating routine postoperative blood tests after conducting robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer (PCa) and proposed recommendations for their use. 

This study reported the long-term effectiveness and safety of the combined treatment of vemurafenib (Zelboraf) and cobimetinib (Cotellic) in patients with previously untreated BRAF-mutated advanced melanoma. The data showed that the combination was safe and effective over the long term.

This study evaluated the effectiveness and safety of regorafenib (Stivarga) versus TAS-102 (Lonsurf; trifluridine-tipiracil) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that both treatments were safe and lead to similar survival outcomes for primary and secondary treatment of patients with unresponsive mCRC.

This review looked at whether sodium-glucose cotransporter 2 (SGLT2) inhibitors can improve non-alcoholic fatty liver disease (NAFLD) for people with type 2 diabetes (T2D). It found that these medications can improve liver function in these patients.

The study reports the outcomes of cancer treatment on the health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (MM) who were not eligible for a stem cell transplant (SCT). This study showed that treatment with VMP (bortezomib, melphalan, and prednisone) with or without daratumumab (Darzalex) improved the HRQoL in these patients. 

This study evaluated the outcomes of autologous stem cell transplantation (ASCT) for patients with recurrent multiple myeloma (MM). This study found that long-term outcomes for these patients were promising, especially for patients who had the transplant right away after a first relapse.

This study looked at vagus nerve stimulation (VNS) as a treatment for arm weakness after stroke. It found that VNS combined with standard rehabilitation improved arm function significantly more than standard rehab alone.